ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Protective Effects and Mechanisms of Extracellular Vesicles in Remote Ischemic Preconditioning on Renal Injury Induced by Inflammation.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
It is known that lipopolysaccharides (LPS) could lead to kidney injury and may play a role in intracavitary lithotripsy surgeries such as percutaneous nephrolithotomy (PCNL). Remote ischemic preconditioning (RIPC) has been demonstrated to have protective effects against kidney injury caused by various factors; however, its role in LPS-induced kidney injury remains unclear and its mechanisms require further exploration. Previous studies have shown that extracellular vesicles (EVs) induced by hypoxia mediated the renal protective effects of RIPC. In this study, we established a kidney injury model in rats by ligating the left ureter and injecting LPS into the renal pelvis, along with simultaneous removal of the right kidney (U-L model); EVs were isolated from the plasma of rats subjected to RIPC or sham treatment and administered to U-L model rats. Separately, EVs obtained from healthy human volunteers were applied to LPS-treated human renal tubular epithelial cells (HK-2). Results indicated that RIPC-EVs(R) reduced kidney injury caused by U-L by inhibiting apoptosis, inflammation, and oxidative stress. In vitro, RIPC-EVs(H) alleviate LPS-induced HK-2 cell injury by attenuating apoptosis and inflammation. Moreover, we identified 37 significantly upregulated differential proteins in the EVs sourced from human plasma after RIPC through 4D label-free proteomics, including Tenascin-C (TNC). Mechanistic studies revealed that RIPC-EVs(H) activated β-catenin, inhibited the p53 and NF-κB signaling pathways, and alleviated kidney injury. Clinical trial data showed that RIPC reduced the expression of kidney injury biomarkers in patients undergoing PCNL for kidney stones. Overall, the present study suggested that RIPC could mitigate kidney injury induced by LPS, possibly through the protective role of Tenascin-C carried by EVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.